Our findings suggest that in obesity, insulin and IGF1 signaling pathway cross-talks with IL-17 signaling pathway through suppressing GSK3 activities, thus enhancing IL-17-mediated inflammation and contributing to the chronic inflammatory status commonly seen in obesity. Here, IL17A is linked to obesity disorder.